Retatrutide Clinical Trial Results: Phase III TRIUMPH Data

The December 2025 TRIUMPH-4 readout reset the ceiling for obesity pharmacotherapy. At the 12mg weekly dose over 68 weeks, participants lost 28.7% of body weight on average, with a matched placebo arm losing 2.1%. Absolute weight loss averaged 32.3 kg (71.2 lbs). No approved weight loss drug, and no other investigational compound in late-stage development, has reported anything close.

TRIUMPH-4 was the first of eight Phase III retatrutide trials to read out. Seven more are expected across 2026, covering type 2 diabetes, cardiovascular outcomes, obstructive sleep apnea, and hepatic endpoints. Eli Lilly has indicated a regulatory filing in late 2026 or 2027, which puts an FDA approval window of 2027 in play if the remaining data lands cleanly.

This article walks through every Phase III result reported to date, the safety signals that emerged (including a new dysesthesia finding not seen in Phase II), how retatrutide compares with semaglutide and tirzepatide trial data, and what to watch for in the remaining readouts.

What retatrutide is, briefly

Retatrutide (development code LY3437943) is Eli Lilly's triple agonist peptide. It activates three incretin and metabolic receptors in parallel: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. The first two receptors are familiar from semaglutide (GLP-1 only) and tirzepatide (GLP-1 plus GIP). The glucagon component is new at this scale. Glucagon receptor activation increases resting energy expenditure and promotes hepatic fat oxidation, which the prevailing mechanistic theory credits for the additional weight loss over dual agonism.

Pharmacokinetics are broadly similar to other weekly GLP-1 agonists: subcutaneous injection, half-life of approximately six days, steady state after four to five weeks. Titration in the TRIUMPH protocols runs 2mg, 4mg, 6mg, then either 9mg or 12mg weekly. The full titration takes roughly 12 weeks before the maintenance dose is reached.

The triple agonist design is the central research question. Dual-agonist tirzepatide added GIP receptor activity to the GLP-1 mechanism and produced a step-change in efficacy over semaglutide. Retatrutide tests whether adding glucagon receptor activity produces a second step-change. The Phase II data suggested yes; TRIUMPH-4 confirms it at the population level. The remaining Phase III trials will determine whether the benefit persists across comorbid populations where the glucagon pathway may behave differently.

What the Phase III research says

TRIUMPH is the umbrella name for the Phase III program. Eight trials are running in parallel, each studying a different population or comorbidity. The program builds on the Phase II trial published in The New England Journal of Medicine in August 2023 (Jastreboff et al., PMID: 37366315), which reported 24.2% weight loss at 12mg over 48 weeks and provided the dosing schedule carried into Phase III.

That Phase II result was what triggered the current level of industry attention. For context, the original semaglutide STEP 1 trial reported 14.9% weight loss, and tirzepatide's SURMOUNT-1 reported 22.5%. Retatrutide exceeded both in Phase II and extended the gap further in Phase III. The dose-response curve also continued to climb at 12mg, suggesting the efficacy ceiling for triple agonism may not have been reached.

TRIUMPH-4: obesity with knee osteoarthritis

TRIUMPH-4 was the first Phase III readout, reported by Eli Lilly in December 2025. It enrolled adults with obesity (BMI 30+) and moderate-to-severe knee osteoarthritis. The trial ran 68 weeks with a roughly 1:1:1 randomisation across 9mg, 12mg, and placebo arms.

The pain score result is notable. WOMAC pain reductions of 4.4 to 4.5 points are clinically meaningful and suggest weight loss translates into functional benefit beyond the scale. The blood pressure reduction at 12mg (-14.0 mmHg systolic) is in the range you would expect from a combination antihypertensive regimen.

The dysesthesia safety signal

The most-discussed finding from TRIUMPH-4 is dysesthesia: abnormal skin sensation, typically described as burning, tingling, or pins and needles. It appeared in 20.9% of 12mg participants, 8.8% of 9mg, and 0.7% of placebo. This signal did not appear in Phase II at the same dose and duration. Phase III ran longer and included more participants, which increases the chance of detecting lower-frequency adverse events, but the jump is large enough that it will face regulatory scrutiny.

Eli Lilly's investor communications characterise the dysesthesia as typically mild-to-moderate and reversible on discontinuation. No cases of permanent nerve injury have been reported in trial disclosures to date. Longer follow-up from the other TRIUMPH trials will clarify whether this is a dose-limiting issue or a manageable side effect profile.

Other Phase III trials in the program

The remaining TRIUMPH trials study obesity plus specific comorbidities: TRIUMPH-1 (obesity), TRIUMPH-2 (obesity with type 2 diabetes), TRIUMPH-3 (cardiovascular outcomes, the longest trial in the program), TRIUMPH-5 (obstructive sleep apnea), and further readouts on hepatic and metabolic endpoints. ClinicalTrials.gov registry numbers include NCT05882045 (TRIUMPH-1), NCT05929066 (TRIUMPH-2), and NCT06662383 (TRIUMPH-3).

TRIUMPH-3 is the most strategically important of the remaining trials. Semaglutide's SELECT trial, which showed a 20% reduction in major adverse cardiovascular events, was what triggered broad insurance coverage and payer acceptance of GLP-1 drugs for obesity. If TRIUMPH-3 produces a comparable or better MACE signal, retatrutide enters the market with an efficacy plus outcomes story that is difficult for competitors to match.

Comparison: retatrutide vs tirzepatide vs semaglutide

The Phase III comparison is indicative rather than head-to-head. Each drug was tested in its own trial with different populations, durations, and design. The useful framing: each mechanism step (GLP-1, then GLP-1 plus GIP, then GLP-1 plus GIP plus glucagon) adds roughly 5 to 7 percentage points of weight loss.

Safety profile sits in the same class family. All four compounds share the GLP-1 gastrointestinal profile: nausea, vomiting, constipation, occasional gallbladder complications. Retatrutide adds the dysesthesia signal. For the full side-by-side, see Retatrutide vs Tirzepatide and Retatrutide vs Semaglutide.

Practical breakdown: what the data means in practice

Retatrutide is investigational. It is not available by prescription, not approved for compounding, and not commercially available through any legitimate pharmacy channel as of April 2026. Grey-market sources exist and are a significant safety concern: purity, sterility, and dosing accuracy cannot be verified outside the clinical trial supply chain. See Retatrutide Side Effects for the full safety profile.

Trial dosing is a useful reference for what approval-era dosing will probably look like. The TRIUMPH schedule runs 2mg, 4mg, 6mg, then 9mg or 12mg weekly, with each step held for approximately four weeks. Discontinuation rates at 12mg were higher than at 9mg, suggesting the efficacy gain at the top dose comes with a tolerability cost. Some discontinuations at 12mg were attributed to perceived excessive weight loss in participants with lower baseline BMI — a novel finding in the class. See Retatrutide Dosage Guide for detailed trial schedules.

Realistic efficacy expectations need to account for trial versus clinical population differences. Real-world weight loss from semaglutide and tirzepatide has run 60 to 75% of trial-reported values. If retatrutide follows the same pattern, a post-approval 12mg user might see 17 to 22% weight loss rather than 28.7%.

FDA approval timeline

Eli Lilly has not disclosed a filing date publicly. Standard timelines: last trial readout, then three to six months to compile the NDA, then a six to ten month FDA review (priority review can compress this). If the cardiovascular outcomes trial reads out mid-2026, the earliest realistic NDA is late 2026, with approval in 2027.

Priority review is a plausible designation. GLP-1 class obesity drugs have received it in the past, and retatrutide would qualify if Lilly can frame the triple-agonist efficacy as a meaningful advance over existing approved therapies. Standard review takes 10 months from filing; priority review takes six. The Retatrutide FDA Approval Timeline article covers the specific catalysts and expected decision dates.

What to watch in the remaining readouts

Three things determine whether retatrutide becomes a clean best-in-class drug or a qualified one. First, whether the dysesthesia signal stays manageable as longer-duration data accumulates. Second, whether TRIUMPH-3 produces a MACE reduction, which would secure broad insurance coverage. Third, whether the diabetes arm's HbA1c data is competitive with tirzepatide, which is already approved for diabetes under the Mounjaro label.

A fourth consideration: durability of weight loss after discontinuation. Semaglutide trials showed roughly two-thirds of weight loss regained within a year of stopping treatment. If retatrutide follows the same pattern, the 28.7% number becomes a chronic-treatment figure rather than a one-time transformation. The TRIUMPH extension studies should start producing discontinuation data from 2026 onward. Our Retatrutide File covers the full pipeline picture.

Frequently asked questions